CORT Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Corcept Therapeutics Inc (CORT) is not a strong buy at the moment for a beginner investor with a long-term strategy. While there are positive catalysts such as FDA approval of Lifyorli and analyst upgrades, the presence of ongoing class action lawsuits, declining net income, and EPS, combined with neutral trading sentiment, suggests a cautious approach. The stock is better suited for monitoring rather than immediate investment.
The MACD is positive and contracting, indicating a mild bullish trend. RSI is neutral at 77.382, and moving averages are converging, showing no strong directional momentum. The stock is trading near its R1 resistance level of 44.008, with support at 40.906, suggesting limited short-term upside.
FDA approval of Lifyorli ahead of schedule, which diversifies Corcept's product portfolio beyond Korlym. Analysts have raised price targets, with Canaccord increasing it to $110 and maintaining a Buy rating.
Multiple class action lawsuits alleging misleading statements about relacorilant's efficacy and FDA communications. Declining net income (-21% YoY) and EPS (-26.92% YoY) in the latest quarter. Insider and hedge fund trading sentiment is neutral, with no significant activity.
In Q4 2025, revenue increased by 11.12% YoY to $202.13M, but net income dropped by 21% YoY to $24.29M, and EPS declined by 26.92% YoY to 0.19. Gross margin improved slightly to 98.74%.
Analysts have a generally positive outlook with multiple Buy ratings. Wolfe Research upgraded the stock to Peer Perform, and Canaccord raised the price target to $110, citing FDA approval of Lifyorli as a significant milestone. However, H.C. Wainwright lowered its price target to $60, reflecting concerns about the sustainability of the core Cushing's franchise and the impact of generic competition.
